Our simulations reveal the efficacy of targeting the growth factors signalling pathway and highlight the potency of PI3K inhibitors in disrupting the aerobic glycolysis in p53-mutated cancer cells, enhancing therapeutic outcomes. The gene discussed is TP53; the disease is cancer.